Specify a stock or a cryptocurrency in the search bar to get a summary
STAAR Surgical Company
SR3STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia. It markets its products to health care providers, including ophthalmic surgeons, vision and surgical centers, hospitals, government facilities, and distributors, as well as products are primarily used by ophthalmologists. The company sells its products directly through its sales representatives in the United States, Japan, Germany, Spain, Canada, the United Kingdom, and Singapore, as well as through own representatives and independent distributors in China, Korea, India, France, Benelux, Italy, and internationally. STAAR Surgical Company was incorporated in 1982 and is headquartered in Lake Forest, California. Address: 25651 Atlantic Ocean Drive, Lake Forest, CA, United States, 92630
Analytics
WallStreet Target Price
139.41 EURP/E ratio
66.2927Dividend Yield
–Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures SR3
Dividend Analytics SR3
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History SR3
Stock Valuation SR3
Financials SR3
Results | 2019 | Dynamics |